TY PHAR.(SZ:002728)2025-05-23 07:22Sales Goals and Market Potential - The company aims to sell 100 million boxes of cough tablets within 3-5 years, with a focus on achieving this target post-reform [1] - The cough tablets have a significant market potential due to low coverage in certain areas, which will be addressed after the marketing organization transformation [2] - The aging population (31 million people aged 60 and above, accounting for 22% of the population) increases the consumer base for cough and phlegm products [2] Product Efficacy and Production Capacity - The cough tablets have a clinical effectiveness rate of 93%, with a significant effect on chronic coughs [1] - Current production capacity is 1.8 billion tablets, with potential to increase to 2.4 billion based on market demand [2] - Sales data shows a recovery trend, with 230 million tablets sold in 2024 and 217 million in Q1 2025 [2] Marketing and Organizational Changes - The company is undergoing a marketing transformation, shifting from a distributor model to a self-operated and promotional service model [3] - New departments have been established to enhance marketing efforts, including self-operated sales, online marketing, and brand market departments [3] - The company is expanding its online sales channels, with significant growth in B2C and O2O platforms [4][11] Brand Development and Consumer Engagement - The company is enhancing brand recognition through a mix of traditional and new media advertising [4][12] - The marketing strategy includes collaboration with major pharmacy chains and community pharmacies to increase consumer education and engagement [5][12] - The company aims to strengthen its brand through targeted advertising and promotional activities across various platforms [5][12] Financial Performance and Product Diversification - In 2023, cough tablets accounted for 41.96% of the company's revenue, indicating a strong reliance on this product [8] - Other products collectively contribute over 50% of revenue, mitigating dependency risks [8] - The company is focusing on promoting other products like skin disease and blood toxin pills to diversify its portfolio [9][10]